MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 2, 2018, MiMedx Group, Inc. (the “Company”) announced the resignation of Parker H. “Pete” Petit as Chief Executive Officer and Chairman of the Company’s Board of Directors (the “Board”), effective as of June30, 2018. Mr.Petit continues to serve as a director of the Board.

The Company also announced the resignation of William C. Taylor as President and Chief Operating Officer of the Company and as a director of the Board, effective as of June30, 2018.

These resignations are based on the Board of Directors’ business judgement regarding the Company’s leadership and direction, and arise, in part, from information the Audit Committee has identified through its previously announced independent investigation. This investigation is ongoing and there may be other actions taken based, at least in part, on information from the investigation.

Charles R. Evans, the Company’s lead director, has been appointed Chairman of the Board.

The Board appointed David Coles to serve as the Company’s Interim Chief Executive Officer, effective as of July2, 2018. Mr.Coles, 53, is a Managing Director with Alvarez& Marsal (“A&M”) where he has been employed since 1997. He has extensive experience helping better position companies for long-term success either through interim C-suite or advisory roles. Throughout his career, Mr.Coles has worked closely with executive teams at both public and private companies across a range of industries to drive business performance improvement and preserve and enhance shareholder value. Mr.Coles has served as CRO of Walter Investment Management, Inc. from June 2017 through February 2018, and as interim CEO of Campus Crest Communities, Inc. from May 2015 through January 2016. Mr.Coles served as well as an adviser to M*Modal Inc. from October 2013 through August 2014, as CFO of PHH Corp from March 2011 through May 2012, as CFO of Lehman Brothers Holdings Inc. from September 2008 through February 2009, as CFO& CRO of Leiner Health Products Inc. from January 2001 through April 2002, and as COO of Applica, Inc. from October 2005 through May 2006.

Item 5.02 Regulation FD Disclosure.

On June2, 2018, the Company issued a press release announcing the leadership changes described in Item 5.02 above. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.02 Financial Statements and Exhibits

(c) Exhibits

MIMEDX GROUP, INC. Exhibit
EX-99.1 2 d655278dex991.htm EX-99.1 EX-99.1 Exhibit 99.1     MIMEDX ANNOUNCES LEADERSHIP CHANGES AND CORPORATE ACTIONS     •   Pete Petit Resigns as Chairman and Chief Executive Officer     •   Charles Evans Appointed Chairman of the Board     •   Bill Taylor Resigns as President and Chief Operating Officer     •   David Coles Appointed Interim Chief Executive Officer     •   Board and Management Take Decisive Action with Initiatives to Improve Corporate Compliance and Internal Operations Marietta,…
To view the full exhibit click here

About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.